Which laboratory tests should be monitored in patients with hyperthyroidism?

Laboratory Monitoring for Hyperthyroidism

The essential laboratory tests to monitor in hyperthyroidism are TSH and free T4, measured every 4–8 weeks during active treatment until euthyroidism is achieved, then every 3–6 months once stable. 1

Initial Diagnostic Laboratory Panel

When hyperthyroidism is suspected, the following tests establish the diagnosis and guide management:

• TSH (thyroid-stimulating hormone) is the primary screening test—suppressed TSH (<0.4 mIU/L) with elevated free thyroid hormones confirms hyperthyroidism 1, 2
• Free T4 (free thyroxine) should be measured alongside TSH to distinguish subclinical from overt hyperthyroidism 1, 2
• Free T3 (free triiodothyronine) is added when TSH is suppressed but free T4 is normal, as some patients have isolated T3 toxicosis 1, 2
• TSH receptor antibodies (TRAb) are strongly recommended for accurate diagnosis of Graves' disease, with sensitivity of 93–97% and specificity of 86–99% 2, 3
• Thyroid peroxidase antibodies (TPO) help identify autoimmune thyroid disease, particularly when distinguishing Graves' disease from Hashimoto's thyroiditis 1, 4

Monitoring During Active Treatment

Once treatment is initiated (antithyroid drugs, radioactive iodine, or surgery preparation), serial monitoring is critical:

• TSH and free T4 every 4–8 weeks during the titration phase of antithyroid drugs to assess response and adjust dosing 1
• Free T3 measurement may be needed if symptoms persist despite normalized TSH and free T4, as T3 can remain elevated 1
• Complete blood count (CBC) should be checked at baseline and if fever, sore throat, or infection develops during antithyroid drug therapy to detect agranulocytosis (a rare but serious side effect) 1
• Liver function tests (ALT, AST, bilirubin) at baseline and if symptoms of hepatotoxicity emerge, as antithyroid drugs can cause liver injury 1

Long-Term Monitoring After Treatment

After achieving euthyroidism or completing definitive therapy:

• TSH and free T4 every 3–6 months for the first year after stopping antithyroid drugs, as recurrence occurs in approximately 50% of patients 1
• Annual TSH and free T4 thereafter for patients in remission, as late recurrence can occur 1
• TSH and free T4 every 6–12 months indefinitely after radioactive iodine or thyroidectomy, as hypothyroidism develops in most patients and requires levothyroxine replacement 1, 5

Special Monitoring Situations

Subclinical Hyperthyroidism (TSH <0.1 mIU/L with normal free T4/T3)

• Repeat TSH and free T4 in 3–6 months to confirm persistence, as transient suppression can occur with non-thyroidal illness 6, 7
• **Treatment is recommended when TSH <0.1 mIU/L persists**, particularly in patients >60 years, due to increased risk of atrial fibrillation (3–5 fold), osteoporosis, and cardiovascular mortality 6, 7
• Monitor for atrial fibrillation with ECG if TSH remains suppressed, especially in elderly patients 6, 7

Pregnancy

• TSH and free T4 every 4 weeks during pregnancy in women with active hyperthyroidism, as thyroid hormone requirements change throughout gestation 1
• TRAb measurement in the third trimester (weeks 18–22 and 32–34) for women with current or past Graves' disease to assess fetal risk of thyrotoxicosis 1

Thyroid Eye Disease (TED)

• Maintain strict euthyroidism with TSH in the normal range (0.4–4.5 mIU/L), as both hyper- and hypothyroidism can worsen TED 8
• Monitor TSH and free T4 every 4–6 weeks during active TED treatment to avoid fluctuations 8

Critical Pitfalls to Avoid

• Do not rely on a single TSH measurement—TSH can be transiently suppressed by non-thyroidal illness, medications (dopamine, glucocorticoids, amiodarone), or pregnancy 6, 9
• Avoid checking TSH alone in suspected hyperthyroidism—always measure free T4 (and free T3 if indicated) to distinguish subclinical from overt disease 1, 2
• Do not overlook assay interference—heterophile antibodies or biotin supplementation can cause falsely abnormal results; if results are discordant with clinical picture, repeat testing with a different assay method 9
• Never delay treatment in overt hyperthyroidism while waiting for antibody results—start antithyroid drugs immediately if TSH is suppressed and free T4/T3 are elevated, as untreated hyperthyroidism increases mortality risk 1, 5
• Recognize that TSH may remain suppressed for months after achieving biochemical euthyroidism with treatment—use free T4 and free T3 to guide dosing adjustments during this recovery phase 1, 9

Age-Specific Considerations

In older adults (>65 years):

• Subclinical hyperthyroidism with TSH <0.1 mIU/L should be treated due to significantly increased cardiovascular and bone risks, even if asymptomatic 5, 7
• Monitor more frequently (every 3–4 months) in elderly patients on antithyroid drugs, as they are at higher risk for complications 5
• Consider lower treatment thresholds for TSH suppression in older adults, as even mild subclinical hyperthyroidism (TSH 0.1–0.4 mIU/L) increases atrial fibrillation risk 3-fold over 10 years 6, 5